Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the proposa...
Two Directors at Prospect Capital Corp bought 1,295,000 shares at between 2.710USD and 2.722USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire Verona Pharma for $107 ...
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces two posters on additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonar...
Heartland Express, Inc. Declares Regular Quarterly Dividend NORTH LIBERTY, Iowa, Sept. 12, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on October 3, 2025, to shareholders of record at the close of business on September 23, 2025. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's eighty-ninth consecutive quarterly cash dividen...
Prospect Capital Corporation and Affiliate Complete $18 Million Investment in The Ridge NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (“Prospect”) (NASDAQ: PSEC) and an affiliate have provided a first lien senior secured term loan, a first lien senior secured revolving credit facility, and an equity investment to TCSPV Holdings IV, LLC (“The Ridge” or “Company”), aggregating approximately $18 million, in collaboration with Thesis Capital Partners. The Ridge is a physician-led addiction treatment facility that delivers personalized care in a luxurious residenti...
Prospect Capital Announces Financial Results for June 2025 NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter and fiscal year ended June 30, 2025. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedQuarter EndedQuarter EndedJune 30, 2025March 31, 2025June 30, 2024 Net Investment Income (“NII”)$79,043$83,489$102,922NII per Common Share$0.17$0.19$0.25Interest as % of Total Investment Income94....
Prospect Capital Schedules Fiscal Year Earnings Release and Conference Call NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company” or “Prospect”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-K containing results for the fiscal year ended June 30, 2024 and to issue its earnings press release on Tuesday, August 26, 2025, after the close of the markets. The Company will host a conference call on Wednesday, August 27, 2025 at 9:00 a.m. Eastern Time. The conference call dial-in number will ...
Heartland Express, Inc. Reports Operating Results for the Second Quarter of 2025 NORTH LIBERTY, Iowa, July 24, 2025 (GLOBE NEWSWIRE) -- Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the three and six months ended June 30, 2025. Three months ended June 30, 2025: Operating Revenue of $210.4 million,Net Loss of $10.9 million, Basic Loss per Share of $0.14,Operating Ratio of 105.9% and 106.0% Non-GAAP Adjusted Operating Ratio(1),Total Assets of $1.3 billion, including $22.9 million of Cash,Stockholders' Equity of $786.7 million,Repurchased 1 million shares of ...
Prospect Capital Corporation Acquires QC Holdings, Inc. NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (“Prospect”) (NASDAQ: PSEC) has announced the closing of the acquisition of QC Holdings, Inc. (“QC Holdings”), a provider of consumer credit, by Prospect on June 30, 2025. In accordance with the previously announced definitive merger agreement, Prospect has acquired QC Holdings in an all-cash transaction for a total enterprise value of approximately $115 million. The common stock for QC Holdings is no longer listed on a stock exchange. QC Holdings, as a p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.